Melanoma

Podcast: Targeted therapy considerations in metastatic melanoma

Wednesday, 5 May 2021


The treatment landscape in advanced melanoma has changed dramatically in the past decade and there is now a choice of therapies available, offering individualised treatment approaches.

In this podcast, A/Professor Victoria Atkinson and A/Professor Matteo Carlino discuss their approaches to therapy, with a particular focus on the use of targeted therapies for advanced BRAF-mutant melanoma.

References: Ascierto P et al. Eur J Cancer. 2020; 126:33-44; Ascierto P et al. Lancet Oncol 2016; 17: 1248–60; BRAFTOVI(encorafenib) Approved Product Information, updated Aug 2019; COTELLIC(cobimetinib) Approved Product Information, updated Aug 2019; Dabrafenib Unresectable Stage III or Stage IV malignant melanoma PBS Listings.https://www.pbs.gov.au/medicine/item/10003L-11820D-11823G-2846T-2954L-2963Y. Accessed 29th April 2021; Dréno B, et al. J Clin Oncol. 2018; 36(Suppl. 15):9522 (Poster presentation); Dummer R, et al, Lancet Oncol. 2018;19(5):603-15; Dummer R, et al, Lancet Oncol. 2018;19(10):1315-27; Encorafenib PBS listings. https://www.pbs.gov.au/medicine/item/11937G-11938H-11949X-11954E. Accessed 29th April 2021; Gogas H et al. Eur J Cancer. 2019; 119: 97-106; Hamid et al. Cancers 2019; 11: 1642; Heinzerling et al. ESMO Open. 2019; 4:e000491; KEYTRUDA(pembrolizumab) Approved Product Information, updated Feb 2021; King AJ, et al. PLoS ONE. 2013; 8: e67583; Koelblinger P et al. Curr Opin Oncol. 2018; 30: 125–133; Larkin et al. N Engl J Med 2014; 371: 1867-76; Larkin J et al. N Engl J Med 2019; 381: 1535-46; Long GV et al NEJM 2014; 371: 1877-88; Long GV et al. Lancet 2015; 386(9992): 444-451; MEKINIST(trametinib) Approved Product Information, updated Mar 2021; MEKTOVI(binimetinib) Approved Product Information, Jan 2019; OPDIVO(nivolumab) Approved Product Information, updated Feb 2021; Robert C et al. NEJM 2011. 364(26):2517-26; Robert C et al. N Engl J Med. 2015; 372: 30–39; Robert C, et al. Ann Oncol. 2016; 27:1–36 (LBA40 and ESMO 2016 presentation); Schachter J et al. Lancet 2017; 390: 1853-62; TAFINLAR (dabrafenib) Approved Product Information, updated Mar 2021; Ugurel et al. Eur J Cancer. 2020; 130:126-138; Vemurafenib PBS listings. https://www.pbs.gov.au/medicine/item/11076Y-11081F. Accessed 29th April 2021; Wolchock JD et al. N Eng J Med 2017; 377:1345-56; YERVOY (ipilimumab) Approved Product Information, updated July 2020; ZELBORAF (vemurafenib) Approved Product Information, updated Mar 2020.

© 2021 Pierre Fabre, all rights reserved. BRAFTOVI® and MEKTOVI® are registered trademarks of Array BioPharma Inc. a wholly owned subsidiary of Pfizer Inc. Pierre Fabre Australia Pty Ltd. ABN 30 098 999 850. North Sydney NSW 2060. BMM_2104_01. Material Approved: April 2021

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2023 the limbic